Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells

Medicinal Chemistry

Volumn 2, Issue 1, 2006, Pages 47-53

  Nguewa, Paul A ^a   Fuertes, Miguel A ^b   Cepeda, Victoria ^b   Alonso, Carlos ^b   Quevedo, Celia ^b   Soto, Manuel ^b   Pérez, José M ^b  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

3 aminobenzamide; Apoptosis; Cancer chemotherapy; PARP 1 Inhibitors; Platinum drugs

Indexed keywords

3 AMINOBENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; HETEROCYCLIC COMPOUND; NEDAPLATIN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PLATINUM DICHLORIDE (4 PICOLINE)(PIPERAZINE); QUINOLINE DERIVATIVE; TRANSPLATIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DNA REPAIR; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; OVARY TUMOR; PRIORITY JOURNAL; TUMOR CELL; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 33746154897     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340606775197697     Document Type: Article

References (29)

1. Fuertes, M.A.; Castilla, J.; Alonso, C.; Perez, J.M. Curr. Med. Chem. 2003, 10, 257.
2. Perez, J.M.; Fuertes, M.A.; Alonso, C.; Navarro-Ranninger, C. Crit. Rev. Oncol. Hematol. 2000, 35, 109.
3. Gonzalez, V.M.; Fuertes, M.A.; Alonso, C.; Perez, J.M. Mol. Pharmacol. 2001, 59, 657.
4. Fuertes, M.A.; Castilla, J.; Alonso, C.; Perez, J.M. Curr. Med. Chem. Anti-Canc. Agenis, 2002, 2, 539.
5. Fuertes, MA.; Castilla, J.; Nguewa, P.A.; Alonso, C.; Pérez, J.M. Med. Chem. Rev.-Online 2004, 1, 187.
6. Fuertes, M.A.; Alonso, C.; Perez, J.M. Chem Rev. 2003, 103, 645.
7. Nguewa, P.A.; Fuertes, M.A.; Valladares, B.; Alonso, C.; Perez, J.M. Prog. Biophys. Mol. Biol. 2005, 88, 143.
8. Nguewa, P.A.; Fuertes, M.A.; Alonso, C.; Perez, J.M. Mol. Pharmacol. 2003, 64, 1007.
9. Southan, G.J.; Szabo, C. Curr. Med. Chem 2003, 10, 21.
10. Martin, D.S.; Bertino, J.R.; Koutcher, J.A. Cancer Res. 2000, 60, 6776.
11. Virag, L.; Szabo, C. Pharmacol. Rev. 2002, 54, 375.
12. Tentori, L.; Balduzzi, A.; Portarena, I; Levati, L.; Vernole, P.; Gold, B.; Bonmassar, E.; Graziani, G. Cell Death Differ. 2001, 8, 817.
13. White, A.W.; Almassy, R.; Calvert, A.H.; Curtin, N.J.; Griffin, R.J.; Hostomsky, Z.; Maegley, K.; Nowell, D.R.; Srinivasan, S.; Golding, B.T. J. Med Chem. 2000, 43, 4084.
14. Nguewa, P.A.; Fuertes, M.A.; Iborra, S.; Najajreh, Y.; Gibson, D.; Martinez, E.; Alonso, C.; Perez, J.M. J. Inorg. Biochem 2005, 99, 727.
15. Perez, J.M.; Kelland, L.R.; Montero, E.I.; Boxall, F.E.; Fuertes, M.A.; Alonso, C.; Navarro-Ranninger, C. Mol. Pharmacol. 2003, 63, 933.
16. Alley, M.C.; Scudiero, D.A.; Monks, A.; Hursey, M.L.; Czerwinski, M.J.; Fine, D.L.; Abbot, B.J.; Mayo, J.G.; Shoemaker, R.H.; Boyd, M.R. Cancer Res. 1988, 48, 589.
17. Najajreh, Y.; Perez, J.M.; Navarro-Ranninger, C.; Gibson, D. J. Med. Chem. 2002, 45, 5189.
18. Nguewa, P.A.; Fuertes, M.A.; Valladares, B.; Alonso, C.; Perez, J.M. Trends Parasitol. 2004, 20, 375.
19. Wang, D.; Lippard, S.J. Nat. Rev. Drug Discov. 2005, 4, 307.
20. Banasik, M.; Komura, H.; Shimoyama, M.; Ueda, K. J. Biol. Chem. 1992, 267, 1569.
21. McLick, J.; Hakam, A.; Bauer, P.I.; Kun, E.; Zacharias, D.E.; Glusker, J.P. Biochim Biophys. Acta 1987, 909, 71.
22. Kato, T.; Suzumura, Y.; Fukushima, M. Anticancer Res. 1988, 8, 239.
23. Chen, G.; Pan, Q.C. Cancer Chemother. Pharmacol. 1988, 22, 303.
24. Cosi, C. Exp. Opin. Ther. Patents 2002, 12, 1047.
25. Petrou, C.; Mourelatos, D.; Mioglou, E.; Dozi-Vassiliades, J.; Catsoulacos, P. Teratog. Carcinog. Mutagen. 1990, 10, 321.
26. Suto, M.J.; Turner, W.R.; Arundel-Suto, C.M.; Werbel, L.M.; Sebolt-Leopold, J.S. Anticancer. Drug Des. 1991, 6, 107.
27. Montero, E.I.; Perez, J.M.; Schwartz, A.; Fuertes, M.A.; Malinge, J.M.; Alonso, C.; Leng, M.; Navarro-Ranninger, C. Chembiochem 2002, 3, 61.
28. Soto, M.; Iborra, S.; Quijada, L.; Folgueira, C.; Alonso, C.; Requena, J.M. Biochem. J. 2004, 379, 617.
29. Fuertes, M.A.; Perez, J.M.; Soto, M.; Lopez, M.C.; Alonso, C. J. Biol, Inorg. Chem. 2001, 6, 107.